Controlled trial of the antigonadotropin danazol in painful nodular benign breast disease.

Abstract

In a double-blind crossover study of the effects of the antigonadotropin danazol on pain and nodularity in 28 women with cyclical mastalgia danazol was given at doses of 200 mg/day and 400 mg/day, and the responses were assessed both subjectively and objectively. Danazol caused a significant and progressive decrease in breast pain and nodularity when compared with placebo. Symptoms responded more quickly with the 400 mg/day dose of danazol than with the 200 mg dose, but the larger dose also caused greater side-effects. Danazol is a useful addition to the range of antihormones that can be used to suppress the symptoms of severe hormone-related benign breast disease.

• Authors: R E Mansel, J R Wisbey, L E Hughes
• Journal: Lancet (London, England) (Lancet) Vol. 1 Issue 8278 Pg. 928-30 (Apr 24 1982) ISSN: 0140-6736 [Print] England
• PMID: 6122770 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Gonadotropins
• Pregnadienes
• Danazol

Topics

• Adult
• Breast Diseases (drug therapy)
• Clinical Trials as Topic
• Danazol (adverse effects, pharmacology, therapeutic use)
• Dose-Response Relationship, Drug
• Double-Blind Method
• Female
• Gonadotropins (antagonists & inhibitors)
• Humans
• Pain (drug therapy)
• Pregnadienes (therapeutic use)
• Random Allocation